Koss Olinger Consulting LLC Makes New Investment in Incyte Co. (NASDAQ:INCY)

Koss Olinger Consulting LLC purchased a new stake in Incyte Co. (NASDAQ:INCY - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 24,283 shares of the biopharmaceutical company's stock, valued at approximately $1,677,000.

A number of other large investors also recently made changes to their positions in the business. Point72 Asset Management L.P. purchased a new stake in Incyte in the 3rd quarter valued at about $156,611,000. Charles Schwab Investment Management Inc. boosted its position in shares of Incyte by 29.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,609,220 shares of the biopharmaceutical company's stock worth $106,369,000 after acquiring an additional 364,169 shares during the last quarter. Candriam S.C.A. boosted its position in shares of Incyte by 27.8% in the fourth quarter. Candriam S.C.A. now owns 1,034,652 shares of the biopharmaceutical company's stock worth $71,463,000 after acquiring an additional 224,919 shares during the last quarter. LBP AM SA purchased a new stake in Incyte in the fourth quarter valued at approximately $13,905,000. Finally, Los Angeles Capital Management LLC increased its position in Incyte by 94.1% during the fourth quarter. Los Angeles Capital Management LLC now owns 407,201 shares of the biopharmaceutical company's stock worth $28,125,000 after purchasing an additional 197,406 shares during the last quarter. Hedge funds and other institutional investors own 96.97% of the company's stock.

Analyst Upgrades and Downgrades

INCY has been the topic of a number of research analyst reports. StockNews.com lowered shares of Incyte from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 12th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Incyte in a report on Friday, January 10th. William Blair lowered Incyte from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 18th. UBS Group started coverage on Incyte in a research note on Tuesday, December 17th. They issued a "neutral" rating and a $77.00 price objective on the stock. Finally, Wells Fargo & Company increased their target price on shares of Incyte from $68.00 to $70.00 and gave the stock an "equal weight" rating in a research report on Thursday, December 19th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $75.13.

Remove Ads

Insider Transactions at Incyte

In related news, EVP Barry P. Flannelly sold 19,807 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the sale, the executive vice president now directly owns 33,567 shares of the company's stock, valued at approximately $2,272,150.23. This represents a 37.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sheila A. Denton sold 599 shares of Incyte stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total transaction of $41,924.01. Following the completion of the transaction, the executive vice president now directly owns 25,848 shares of the company's stock, valued at approximately $1,809,101.52. This represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,827 shares of company stock valued at $3,322,618. Insiders own 17.60% of the company's stock.

Incyte Stock Up 2.2 %

NASDAQ INCY traded up $1.34 during mid-day trading on Friday, reaching $61.92. 4,332,207 shares of the company's stock traded hands, compared to its average volume of 2,264,889. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The company has a fifty day simple moving average of $70.61 and a 200-day simple moving average of $70.13. The company has a market cap of $11.98 billion, a price-to-earnings ratio of 229.34, a P/E/G ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. As a group, equities research analysts expect that Incyte Co. will post 4.86 EPS for the current year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.